Biomarker ID | 518 |
PMID | 20171670 |
Year | 2010 |
Biomarker | Prostate Health Index (phi) |
Biomarker Basis | Concentration Based (ng/ml) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs Benign Sample |
Type of Biomarker | Diagnostic |
Cohort | 2037 men were screened for prostate cancer, and 322 were reccomended for biopsy. Out of these, 74 men complied out of which, 3 had a total PSA of 2.5 to 10 ng/ml and nonsuspicious DRE. |
Senstivity | 88.5% |
Specificity | 64.9% |
AUC | 0.77 |
Accuracy | NA |
Level Of Significance | NA |
Method Used | Beckman Coulter ACCESS® 2 immunoassay |
Clinical | No |
Remarks | p2PSA provides improved discrimination between prostate cancer and benign disease in screened men with a prostate specific antigen of 2.5 to 10 ng/ml and a negative digital rectal examination. phi = (p2PSA/fPSA) X sqrt(PSA) |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | Others |